|
ALZHEIMER DISEASE 5
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Transfection of GP73-SphK1sR-Ad5 significantly upregulated E1A and downregulated SphK1 in Huh7 cells, but not in HL7702 cells.
|
31749347 |
2020 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer.
|
31541350 |
2019 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Then we utilized small interfering RNAs (siRNAs) to silence GOLM1 expression in GBM U87 and U251 cells.
|
30935831 |
2019 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Using five bioinformatics analysis software, we identified Golgi protein 73 (GP73) as a putative target of microRNA-27b (miR-27b), which is closely related to various biological processes or diseases such as bone metabolism disease, adipose cell and muscle cell development, pulmonary hypertension, cervical cancer, and breast cancer.
|
30418194 |
2019 |
|
Lymphatic Metastasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In HCC group, GP73 level significantly increased in patients with lymphatic metastasis; moreover, GP73 level in Child-Pugh Class B and C groups was statistically significantly higher than that in Child-Pugh Class A group (P < 0.05).
|
30488837 |
2019 |
|
Hereditary spherocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Next‑generation sequencing was used, and the genetic source of HS was identified as a GOLM1 gene mutation.
|
30896804 |
2019 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evaluation of Salivary Exosomal Chimeric <i>GOLM1-NAA35</i> RNA as a Potential Biomarker in Esophageal Carcinoma.
|
30745298 |
2019 |
|
Portal Vein Thrombosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, down-regulated expression of miR-27b was closely correlated with serum GP73, tumor-node-metastasis stage, tumor size, and portal vein thrombosis.GP73 mRNA might be a target of miR-27b.
|
30418194 |
2019 |
|
Cirrhosis and chronic liver disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Increased GP73 expression in hepatocytes from patients with acute hepatitis, through disease progression to cirrhosis and chronic liver disease suggests that progressive tissue remodeling and fibrogenesis are driving forces for GP73 upregulation.
|
30615900 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with GOLPH2-directed antibodies induces durable responses in colorectal and lung cancer models.
|
31541350 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway.
|
30935831 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway.
|
30935831 |
2019 |
|
Tubular Aggregate Myopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Through GRP78, the secreted GP73 stimulated ER stress activation in neighboring macrophages, which then released cytokines and chemokines involved in the tumor-associated macrophage (TAM) phenotype.
|
30723919 |
2019 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with GOLPH2-directed antibodies induces durable responses in colorectal and lung cancer models.
|
31541350 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with GOLPH2-directed antibodies induces durable responses in colorectal and lung cancer models.
|
31541350 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Then we utilized small interfering RNAs (siRNAs) to silence GOLM1 expression in GBM U87 and U251 cells.
|
30935831 |
2019 |
|
MYELOPROLIFERATIVE SYNDROME, TRANSIENT
|
0.010 |
Biomarker
|
disease |
BEFREE |
Through GRP78, the secreted GP73 stimulated ER stress activation in neighboring macrophages, which then released cytokines and chemokines involved in the tumor-associated macrophage (TAM) phenotype.
|
30723919 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer.
|
31541350 |
2019 |
|
Metastatic Gastric Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transplanted tumor model was constructed to analyze the influence of GOLM1 on GC cell growth in vivo.
|
31640085 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that GP73 promotes bladder cancer invasion and metastasis by inducing the EMT through down-regulating WT1 levels and activating the TGF-β1/Smad2 signalling pathway.
|
29349903 |
2018 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that GP73 promotes bladder cancer invasion and metastasis by inducing the EMT through down-regulating WT1 levels and activating the TGF-β1/Smad2 signalling pathway.
|
29349903 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Golgi Phosphoprotein 2 Is Associated With Poor Prognosis in Oral Squamous Cell Carcinoma.
|
29788173 |
2018 |
|
Cholestasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis.
|
29256057 |
2018 |
|
Osteoporosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GOLM1 antibody, glutamine metabolism inhibitors EGCG and BPTES were used to treat ovariectomy (OVX)-induced osteoporosis.
|
30396165 |
2018 |
|
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we infer that GOLM1 might serve as a valuable prognostic biomarker in LUAD, but not in LUSC.
|
29843532 |
2018 |